Interactions médicamenteuses entre antirétroviraux et chimiothérapies et thérapies ciblées (notice n° 271370)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03176cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112080540.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Courtillat, Emeline |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Interactions médicamenteuses entre antirétroviraux et chimiothérapies et thérapies ciblées |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 43 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméLes interactions entre les traitements du VIH et du cancer sont nombreuses et peuvent avoir des conséquences cliniques majeures, nécessitant une attention particulière pour éviter la survenue de toxicités sévères ou un échappement thérapeutique. Elles sont principalement dues à des toxicités additives ou à des interactions liées aux voies métaboliques communes au niveau des transporteurs membranaires et/ou des enzymes hépatiques, en particulier du cytochrome P450. Ce potentiel d’interactions élevé, bien connu avec la chimiothérapie classique, reste également significatif avec les nouvelles thérapies ciblées, la majorité de ces molécules étant également substrats, inhibiteurs et/ou inducteurs des enzymes hépatiques et/ou des transporteurs. Il est donc particulièrement important de les évaluer avant d’initier un traitement anticancéreux chez un patient infecté par le VIH. De ce fait, les réunions de concertation pluridisciplinaire sont fortement conseillées pour optimiser la prise en charge thérapeutique et ainsi préserver à la fois l’efficacité et la survenue d’effets indésirables sévères pouvant mettre en jeu le pronostic vital. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Drug-drug interactions (DDI) between treatments for HIV infection and cancer disease are frequent and often clinically relevant, requiring particular attention to avoid severe acute toxicities or therapeutic failure. Interactions are mainly due to additive toxicities or common metabolic pathways via hepatic enzymes, such as cytochrome P450 enzymes and/or drug transporters. The high potential for DDI, which is widely recognised in classic chemotherapy, remains significant with new targeted cancer therapies, as the majority of these drugs are also substrates, inhibitors and/or inducers of drug transporters and hepatic enzymes. Thus, this highlights the urgent need for their evaluation in HIV-infected patients before starting cancer treatment. For this reason, multidisciplinary staff meetings are strongly advised to discuss the most appropriate therapeutic strategy in order to maintain treatment efficacy and prevent the occurrence of severe acute toxicities, which may be life-threatening. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antirétroviraux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapies ciblées |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | interactions |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antiretroviral therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drug-drug interactions |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | targeted therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Veyri, Marianne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Spano, Jean-Philippe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Solas, Caroline |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 5 | 6 | 2019-11-01 | p. 318-322 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-6-page-318?lang=fr">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2019-6-page-318?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux